The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

Patrick Y Wen¹, Roger J Packer^{2

3}

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Division of Neuro-Oncology, Department of Neurology, Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC, USA.
³ Departments of Neurology and Pediatrics at the George Washington University, Washington, DC, USA.

Editorial

Patrick Y Wen et al. Neuro Oncol. 2021.

. 2021 Aug 2;23(8):1215-1217.

doi: 10.1093/neuonc/noab120.

Patrick Y Wen¹, Roger J Packer^{2

3}

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Division of Neuro-Oncology, Department of Neurology, Brigham and Woman's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC, USA.
³ Departments of Neurology and Pediatrics at the George Washington University, Washington, DC, USA.

No abstract available

Comment on

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. Louis DN, et al. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. Neuro Oncol. 2021. PMID: 34185076 Free PMC article. Review.

1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
1. Jones DTW, Kieran MW, Bouffet E, et al. . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20(2):160–173. - PMC - PubMed
1. Reinhardt A, Stichel D, Schrimpf D, et al. . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273–291. - PubMed
1. Fukuoka K, Mamatjan Y, Tatevossian R, et al. . Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020;22(10):1474–1483. - PMC - PubMed
1. Baroni L, Sundaresan L, Heled A, et al. . Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1372–1381. - PMC - PubMed